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Abstract
The prevalence of asthma and allergic disease has increased in many countries and there has been speculation that immunization promotes
allergic sensitization. Bordetella pertussis infection exacerbates allergic asthmatic responses. We investigated whether whole-cell pertussis
vaccine (Pw) enhanced or prevented B. pertussis induced exacerbation of allergic asthma. Groups of mice were immunized with Pw, infected
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dith B. pertussis and/or sensitized to ovalbumin. Immunological, pathological and physiological changes were measured to assess the impact
f Pw immunization on immune deviation and airway function. Pw immunization modulated ovalbumin-specific serum IgE production,
nd reduced local and systemic IL-13 and other cytokine responses to sensitizing allergen. Histopathological examination revealed Pw
mmunization reduced the severity of airway pathology and decreased bronchial hyperreactivity to methacholine exposure. Pw does not
nhance airway IL-13 and consequently does not enhance but protects against the exacerbation of allergic responses. We find no evidence
f Pw contributing to allergic asthma, but rather provide evidence of a mechanism whereby whole-cell pertussis vaccination has a protective
ole.
2004 Elsevier B.V. All rights reserved.
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. Introduction
Asthma is a chronic disease of the respiratory tract of in-
reasing prevalence in developed societies [1]. The current
nderstanding of allergic asthma is that it results from a break-
own in the normal tolerance to inhaled antigens, associated
ith Th2 cytokine production [2,3]. The inflammatory re-
ponse in asthma is tightly associated with airway hyperre-
ponsiveness, increased mucus production and an infiltration
f the bronchial mucosa with CD4+ T-cells [4]. There is ev-
dence of an altered local T-cell response in favour of Th2
ytokine release (IL-4, IL-5 and IL-13) resulting in B-cell iso-
ype switching to IgE, recruitment of eosinophils, basophils
nd mast cells and production of inflammatory mediators [5].
∗ Corresponding author. Tel.: +353 1 7083835; fax: +353 1 7086337.
E-mail address: bpmahon@may.ie (B.P. Mahon).
The murine OVA model of airway hyperresponsiveness ex-
hibits many of the features of human asthma, including air-
way hyperreactivity, inflammation and increased serum IgE
levels [6,7]. Th2 cells secreting IL-4, IL-5, and IL-13 play a
central role in initiating and sustaining the asthmatic response
in this model [8]. While Th2 cells promote airway inflamma-
tion in asthma, it has been proposed that Th1 cells protect
against allergic disease by antagonizing Th2 activity. Infec-
tious diseases that induce Th1 type responses, might hamper
the development of allergen-specific Th2 cells and prevent
allergy [9].
Epidemiological and clinical studies have suggested a link
between the relative absence of infectious diseases and the
increase in allergic disorders [10,11]; this is referred to as the
‘hygiene hypothesis’. It predicts that infections prevent the in-
duction of allergen-specific Th2 cells through antagonism or
the induction of regulatory T-cells, particularly during neona-
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tal and early childhood development [10,12]. However, there
are data that confound this interpretation, increased IFN-
is seen in asthmatic patients compared with normal sub-
jects [3,13]. Allergen-specific Th1 cells also fail to counter-
act airway hyperresponsiveness in murine models [14]. Fur-
thermore, several studies have suggested that viral/bacterial
infections do not protect but exacerbate disease. Respiratory
syncytial virus, commonly associated with lower lung in-
fections in infancy, is known to exacerbate asthma [15,16],
as does Bordetella pertussis [17]. Consequently, competing
interpretations for the pathogenesis of asthma have been pro-
posed [18,19].
B. pertussis is a Gram-negative bacterium and the
causative agent of pertussis or “whooping cough”, a respi-
ratory disease that remains a significant cause of morbidity
and mortality in infants worldwide. It is a highly contagious
disease, and can occur at any age, though severe illness is
more common in young un-immunized children. B. pertussis
infection induces Th1 responses [20,21] and can be mod-
elled by respiratory challenge of mice, which correlates well
to responses in humans [22].
There has been speculation about the possible promotion
of allergy by common childhood vaccinations [23,24]. A
substantial proportion of children predisposed to allergy and
asthma may not be fully immunized because of public appre-
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immunization induces a similar immune response to infec-
tion [34] and that although variables such as route, dose
and timing influence T-cell responses in animal models, Pw
is a consistent inducer of Th1 responses [20]. In order to
test whether immunization with Pw exacerbated asthma, we
employed a well-characterized murine model of whole-cell
pertussis vaccination and B. pertussis infection in combina-
tion with the murine OVA model of airway hyperrespon-
siveness. We show that although Pw induces a Th1 type
immune response to B. pertussis infection, it does not ex-
acerbate pathology in a model of allergic asthma. Our find-
ings demonstrate that Pw immunization prevents B. pertus-
sis enhancement of OVA-induced IL-10 and IL-13, which
results in a subsequent decrease in airway hyperresponsive-
ness and pathology. This study finds no evidence of a mech-
anism to support speculation linking Pw immunization and
asthma.
2. Materials and methods
2.1. Animals and experimental approach
6- to 8-week-old female BALB/c (Harlan, UK) mice
were used under the guidelines of the Irish Department
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tension surrounding immunization [25]. A number of stud-
es have analysed the prevalence of allergic sensitization and
topic disease in relation to immunization [24,26]. Gruber et
l. found that children with higher immunization coverage
eemed to acquire transient protection against development
f atopy in the first years of life [26]. In contrast, Hurwitz
nd Morgenstern suggested that diphtheria/pertussis/tetanus
DTP) immunization appeared to be associated with an in-
reased risk of subsequent asthma or other allergies [24].
Two different types of pertussis vaccine have been em-
loyed in infant immunization programmes. The whole-cell
ertussis vaccine (Pw) consists of heat/formalin inactivated
irulent whole bacteria whereas the pertussis acellular vac-
ine (Pa) is composed of purified components of the bacteria
Pa), typically including inactivated pertussis toxin. Pw im-
unization has a high efficacy and is associated with the
nduction of antigen-specific Th1 cells [21,27,28], but has
een associated with reactogenicity. In contrast Pa immu-
ization induces a mixed Th1/Th2 response in children and
n murine models, but has reduced reactogenicity [29]. It has
een suggested that promotion of allergy may occur directly,
y administering potentially pro-allergic vaccines, or indi-
ectly, by hindering the Th1-promoting effect of infectious
gents. Pertussis vaccination acts as an adjuvant for antigen-
pecific responses in laboratory animals [30]; active pertussis
oxin, is known to enhance immunoglobulin E (IgE) forma-
ion in animal models [31] and has been linked with a shift
oward Th2-like cytokines in humans [32,33].
Infection withB. pertussismodulates allergen priming and
he severity of airway pathology in a murine model of al-
ergic asthma [17] and we have previously shown that Pwf Health and the research ethics committee of the Na-
ional University of Ireland Maynooth. The experimental
pproach is outlined in Table 1, briefly groups of mice
ere immunized with whole-cell pertussis vaccine (Pw),
nfected with B. pertussis, and then sensitised to ovalbu-
in (OVA) at the peak of infection as detailed below. Con-
rol mice received similar treatment in which 0.9% (w/v)
aq) NaCl (hereafter termed Saline) replaced experimental
reatment.
.2. Immunization, sensitization and airway delivery of
VA
Four groups of at least thirty-five 6–8-week-old female
ALB/c mice (Pw, PwBp, PwOVA and PwBpOVA) were
mmunized i.p. with 0.16 I.U. of whole-cell pertussis vaccine
Pw) (Third International Standard, 1998, pertussis whole-
ell vaccine, NIBSC, UK), equivalent to 1/25th of the hu-
an dose according to the schedule outlined in Table 1. At
day mice were infected with B. pertussis, selected groups
ere then sensitized with ovalbumin (OVA). Sensitization
nvolved 100g OVA (Grade V; Sigma, Dorset, UK) emul-
ified in Alhydrogel® adjuvant (Superfos Biosector, Swe-
en) (1 mg/mouse aluminium hydroxide) administered as
.2 ml i.p. at 10 and 24 days. Control group (Ctrl) received
aline alone (i.p.). On 35, 36, and 37 days, PwOVA and
wBpOVA sensitized mice received 10l containing 50g
VA intra-nasally (i.n.) whereas remaining groups received
aline only (Table 1). All experiments were repeated at least
wice.
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Table 1
Experimental design
Time (days)
−42 −14 0 10 24 35/36/37
Groupa
Pw Pw Pw Saline aerosol Saline (i.p.) Saline (i.p. and i.n.) Saline (i.n.)
Pw and B. pertussis infection
(PwBp)
Pw Pw B. pertussis aerosol infection Saline (i.p.) Saline (i.p. and i.n.) Saline (i.n.)
Pw and OVA sensitization
(PwOVA)
Pw Pw Saline aerosol OVA (i.p.) OVA (i.p and i.n.) OVA (i.n.)
Pw, B. pertussis infection
and OVA sensitization
(PwBpOVA)
Pw Pw B. pertussis aerosol infection OVA (i.p.) OVA (i.p and i.n.) OVA
Groupb
Control (Ctrl) Saline (i.p.) Saline (i.p.) Saline aerosol Saline (i.p.) Saline (i.p. and i.n.) Saline (i.n.)
B. pertussis infection (Bp) Saline (i.p.) Saline (i.p.) B. pertussis aerosol infection Saline(i.p.) Saline (i.p. and i.n.) Saline (i.n.)
OVA sensitization (OVA) Saline (i.p.) Saline (i.p.) Saline aerosol OVA (i.p.) OVA (i.p and i.n.) OVA (i.n.)
B. pertussis infection and
OVA sensitization (BpOVA)
Saline (i.p.) Saline (i.p.) B. pertussis aerosol infection OVA (i.p.) OVA (i.p and i.n.) OVA (i.n.)
a Groups of 6–8-week-old female BALB/c mice were immunized (i.p.) and boosted with whole-cell pertussis vaccine (Pw) at−42 and−14 days. On 0 day,
mice were either sham infected or infected with B. pertussis (Bp) by aerosol. At 10 and 24 days selected groups were sensitised to OVA by i.p alone or i.p and
i.n. routes, respectively. On 35, 36 and 37 days mice were exposed to either saline or OVA by the i.n. route (i.e. 25, 26, and 27 days post-OVA priming and after
bacterial clearance). Bacterial burdens in the airways were measured between 0 and 37 days. All other readouts, including plethysmography were performed
at 37 days.
b For comparison, further groups of unimmunized (sham immunized) mice were treated as follows: control (Ctrl) mice were sham infected on 0 day and
sham sensitised with saline. A second group (Bp) were infected with B. pertussis at 0 day and sham sensitized. The third group (OVA) were sham infected
but sensitized with OVA (100g, i.p.) at 10 and 24 days and again (50g i.n.) at 24, 35, 36, and 37 days. A separate group (BpOVA) were infected with
B. pertussis on 0 day, and sensitized as above. Each experiment was repeated at least twice, on each occasion n> 35 mice per group, bacterial burdens were
measured between 0 and 37 days, all other readouts were at 37 days.
2.3. B. pertussis aerosol infection
Respiratory infection was initiated by aerosol challenge
with B. pertussis strain W28, following growth under agita-
tion conditions at 37 ◦C in Stainer-Scholte liquid medium.
Bacteria from a log-phase culture were resuspended at a con-
centration of 2× 1010 CFU/ml in 1% (w/v) casein in 0.9%
(w/v) saline. The challenge inoculum was administered to
groups of mice on 0 day (Bp, PwBp and PwBpOVA groups).
Administration was by aerosol over a period of 15 min using
a nebulizer. Groups of four or more mice were killed at vari-
ous time points after aerosol challenge to assess the number
of viable B. pertussis in the lungs. Remaining mice received
a similar aerosol of sterile saline alone.
2.4. Enumeration of viable bacteria in the lungs
Lungs were removed aseptically into 1 ml of sterile physi-
ological saline with 1% casein. One hundred microlitres of se-
rially diluted homogenate from individual lungs were placed
onto triplicate Bordet-Gengou agar plates and the number of
CFU determined after incubation at 37 ◦C for 4 days. Re-
sults are reported as the mean number of B. pertussis CFU
(±S.E.M.) for individual lungs, each determined in triplicate,
from four or more mice per time point. All experiments were
repeated twice.
2
c
and aspiration of 0.5 ml PBS per mouse. This was pooled
from five mice (total 2.5 ml) per experimental group. All ex-
periments were performed at least twice. Diluted BALF was
assessed for the presence of cytokines.
2.6. Measurement of OVA and B. pertussis-specific
antibody
OVA and B. pertussis-specific IgG1, 2a, 2b, and 3 present
in collected sera were measured on day 37 by ELISA as pre-
viously described [35,36]. Total and OVA-specific IgE was
measured using a rat anti-mouse IgE monoclonal antibody
(BD, Pharmingen, San Diego, CA, USA). The IgE concen-
tration was expressed as g/ml after comparison to murine
IgE standards.
2.7. T-cell proliferation assays
Spleen cells (2× 106/ml) from infected, sensitized and
control mice (n= 4 or more per group) were tested for
in vitro proliferation against heat-inactivated B. pertussis
(1× 104 CFU/ml), OVA (20g/ml), Concanavalin A (Con
A) (5g/ml, positive control), or medium alone (negative
control). After 72 h, cell proliferation was assessed by liquid
scintillation counting of [3H]-thymidine incorporation and
results were expressed as mean CPM of triplicate wells±S.E.
A
c
t
f.5. Bronchoalveolar lavage
Bronchoalveolar lavage fluids (BALF) were obtained by
annulation of the trachea followed by repeat administrationt the 72 h time point, culture supernatants were sampled for
ytokine analysis, although the kinetics of cytokine produc-
ion varies this time point has previously proved acceptable
or detection of most cytokines [22].
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2.8. Cytokine measurement
Concentrations of IL-5, IL-10, IL-13 and IFN- from
spleen, and BALF were assessed by ELISA (BD, Pharmin-
gen, San Diego, CA, USA). Cytokine concentrations were
calculated by comparison with known cytokine standards as
previously described [35], all determinations were made in
triplicate, results are presented as mean cytokine concentra-
tion (±S.E.M.).
2.9. Whole body plethysmography
Airway responsiveness on day 37 was assessed by metha-
choline (MCh) induced airflow obstruction from conscious
mice using whole-body plethysmography (Buxco Electron-
ics, Sharon, CT, USA) as previously described [37]. Pul-
monary airflow obstruction was measured by enhanced pause
(PenH), a value determined from the ratio of expiratory time
and relaxation time to peak expiratory flow and peak inspi-
ratory flow and thought to correlate with airway responsive-
ness. Measurements were obtained after exposure of mice
for 3 min to PBS (baseline) followed by incremental doses
(3.3 mg–50 mg/ml) of MCh delivered by aerosol [38].
2.10. Respiratory tract histology
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Fig. 1. Course of B. pertussis infection in experimental and control mice.
Groups of mice were sacrificed at intervals after challenge and the number
of viable bacteria estimated by performing colony counts on individual lung
homogenates. Results are representative from two experiments and are pre-
sented as mean (±S.E.M.) CFU in the lungs, determined individually from
four mice at each time point, and for each experimental group. Data for Ctrl
and OVA groups have been offset from zero for clarity.
sis infection and Pw immunization induce a powerful Th1
response [29]. In order to examine immune cross-regulation
and potential interference with immunization, we tested
the effect of OVA sensitization upon the development of
a protective response to infection in Pw immunized and
non-immunized mice. Mice received combinations of OVA
sensitization, Pw immunization and aerosol challenge with
virulent B. pertussis (Table 1). Groups of mice infected with
B. pertussis (Bp and BpOVA) showed similar kinetics of
bacterial clearance (Fig. 1), indicating that OVA sensitization
does not influence bacterial clearance rates. Likewise, OVA
sensitized and non-sensitized mice that had been immunized
prior to bacterial challenge (PwBpOVA and PwBp, respec-
tively) showed identical kinetics of clearance. No bacteria
were recovered from the OVA sensitised or control (Ctrl)
groups, which were uninfected but received saline by aerosol
(Fig. 1). The bacterial burden in the Bp and BpOVA groups
peaked at 10 days and declined thereafter. Pw immunized
mice cleared subsequent infection by B. pertussis by 7
days. In contrast unimmunized mice (Bp and the BpOVA
groups) only showed complete bacterial clearance by 35
days (Fig. 1). Therefore sensitization with OVA did not
impair vaccine-mediated clearance of B. pertussis in this
model.
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IAnimals (n= 5 per group per experiment) were sacrificed
t 37 days. Lungs were removed, fixed in a paraformalde-
yde/lysine/periodate fixative, paraffin embedded, sectioned
nd stained using the haematoxylin and eosin (H&E),
iscombes (identification of eosinophils), alcian blue
identification of mucus), PAS (assessment of basement
embrane thickness), azure-A (identification of mast
ells) and Van Gieson (identification of fibrosis) methods.
istopathological changes evident were graded according
o a semi-quantitative scoring system as mild, moderate
r severe by two researchers without prior knowledge of
he treatment group using a previously established scoring
ystem [17]. All experiments were performed at least twice.
.11. Statistical methods
Results are expressed as the mean±S.E.M. of the indi-
ated number of animals. A Student’s t-test was used to deter-
ine significance among the groups. A value of P< 0.05 was
onsidered significant. Analyses were performed using the
raph-Pad PrismTM software (GraphPad, San Diego, CA).
. Results
.1. Ovalbumin sensitization does not impair
accine-mediated clearance of B. pertussis
The murine OVA model of airway hyperresponsiveness
nduces a powerful Th2 response [7] whereas both B. pertus-.2. OVA-specific IgE production is modulated by Pw
mmunization
The goal of this study was to examine the influence of
w immunization on responses associated with allergic sen-
itization. Although OVA-induced sensitization does not im-
air vaccine-mediated clearance of B. pertussis, it was pos-
ible that Pw influenced allergic sensitization. OVA-specific
gG was not detected from mice infected with B. pertussis
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Fig. 2. Serum IgE and IgG subclasses elicited by Pw vaccination, bacterial infection and allergic sensitization. (A) B. pertussis or (B) OVA-specific serum
antibody responses by IgG subclasses elicited in whole-cell B. pertussis (Pw), vaccinated plus Bp infection (PwBp), vaccinated plus sensitized (PwOVA),
or in mice vaccinated then infected with B. pertussis prior to sensitization (PwBpOVA), response from mice that received OVA sensitization alone (OVA)
or combined with infection (BpOVA) are shown for comparison. (C) B. pertussis-specific serum IgE and (D) OVA-specific serum IgE present from each
experimental group. Results are representative of two experiments expressed as geometric mean titre or ng/ml of antibody (±S.E.M.) from four animals each
determined independently in triplicate. *P< 0.05 compared to the PwOVA treated group.
only; similarly B. pertussis-specific IgG could not be de-
tected in OVA sensitized animals, suggesting no significant
cross-reaction between the two immunogens (Fig. 2A and
B). An analysis of the serum antibody subclasses evoked
revealed that Pw predominantly induced pertussis-specific
IgG2a (Fig. 2A) as previously reported [28,34]. IgG2a
remained the dominant subclass of pertussis-specific anti-
body when Pw immunization was combined with OVA sen-
sitization (PwOVA) or B. pertussis infection (PwBp) al-
though IgG1 and IgG3 was detected in the latter groups
(Fig. 2A). Pw immunization prior to OVA sensitization
(PwOVA) did not significantly alter the dominant OVA-
specific IgG1 response. Infection of these mice with B. per-
tussis (PwBpOVA) did not broaden the subclasses of OVA-
specific antibody detected although the titer was increased
(Fig. 2B). Taken together, these data indicate that Pw im-
munization does not modulate serum IgG subclasses in-
duced by allergic sensitization. In contrast to the conser-
vative effects on serum IgG subclasses, significant differ-
ences were observed in the induction of IgE (Fig. 2C and
D). Pw induces little B. pertussis-specific IgE, and this is
not altered by OVA sensitization or infection (Fig. 2C).
OVA sensitization induces high levels of OVA-specific IgE
but this is significantly reduced by prior Pw immunization
(Fig. 2D). However, a combination of immunization and in-
f
d
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3.3. Pw immunization prevents B. pertussis
enhancement of OVA-induced IL-10 and IL-13
B. pertussis infection enhances OVA-induced IL-10 and
IL-13 [17]. Pw immunization has hitherto been regarded as
inducing essentially similar immune responses to those in-
duced by infection [22]. In order to dissect the influence of
immunization on airway hyperresponsiveness, we examined
cell-mediated immune responses in the various study groups.
Pw immunization alone or in combination with B. pertussis
infection (Pw or PwBp) induced very little IL-5 but strong
IFN- responses (Fig. 3A and B). This was consistent with
the protection observed earlier (Fig. 1) and previous data
[34]. Pw immunization reduced levels of IL-5, IL-13 and
IFN- (Fig. 3A–C) in all immunized groups suggesting that
Pw immunization prevents live B. pertussis enhancement of
these indices; mirroring the reduction in OVA-specific IgE
(Fig. 2D). Interestingly, previous results have shown that B.
pertussis infection induced specific IL-10 as well as IL-13
responses [17]. Here we demonstrate that in contrast to in-
fection, Pw-immunization resulted in significantly reduced
levels of IL-10, and IL-13 (Fig. 3A–D).
To extend these findings, we examined the levels of cy-
tokines present in bronchoalveolar lavage fluid (BALF) from
each group of mice. Pw immunization alone induced little or
n
z
oection prior to OVA sensitization resulted in a significant re-
uction of IgE (P< 0.05) (Fig. 2D) compared to the PwOVA
roup.o detectable cytokines in BALF. As expected, OVA sensiti-
ation induced high levels of IL-5, -10 and -13 but the levels
f IL-10 and -13 in particular, known to rise in infected mice,
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Fig. 3. Cell mediated immune responses from spleen, elicited by Pw vaccination, bacterial infection and allergic sensitization. IL-5 (A), IFN- (B), IL-13 (C) and
IL-10 (D) responses from spleen cell cultures stimulated with medium alone (−ve control, horizontal shading), heat inactivated B. pertussis at 1× 104 CFU/ml
(hatched bar), OVA (open bar) or Con A (+ve control, black bar). Responses are representative of duplicate experiments each performed in triplicate on
individual samples from four mice per group and are expressed as mean (±S.E.M.). *P< 0.05 compared to the PwOVA treated group.
were reduced in immunized mice that had been infected with
B. pertussis (PwBpOVA) (Fig. 4A–D).
3.4. Pw immunization prior to B. pertussis infection
decreases bronchial hyperresponsiveness to sensitizing
antigen
It has been proposed that prior Th1 responses to bac-
terial infections protect against allergic disease however,
Th1-inducing B. pertussis infection exacerbates airway
hyperresponsiveness in OVA sensitized mice. It might be
predicted that Pw, which induces a very similar immune
response to B. pertussis would have a similar exacerbating
influence. In fact, this is not the case. We used whole body
plethysmography as a surrogate measure of airway reactivity
in mice immunized with Pw and infected with B. pertussis
prior to OVA sensitization (Fig. 5). Prior immunization with
Pw does not enhance but protects against B. pertussis exacer-
bated airway hyperresponsiveness in comparison to controls.
Statistical analysis using two-way analysis of variance
(ANOVA) showed that mice vaccinated with Pw, and sensi-
tized to OVA following B. pertussis infection (PwBpOVA)
displayed significantly reduced bronchial hyperreactivity
compared to BpOVA sensitized animals (P< 0.05) (Fig. 5D).
Thus demonstrating that vaccination with Pw protects
against B. pertussis exacerbation of allergic asthma.
B. pertussis infection is known to modulate the quality of
the inflammatory influx of the respiratory tract, with a marked
reduction in eosinophil numbers accompanied by varying
degrees of epithelial hyperplasia, mucous metaplasia, and
airway pathology [17]. Lung tissue was assessed histolog-
ically (Table 2). Minimal pathology was observed in mice
immunized with Pw or those immunized and infected with
B. pertussis (PwBp) (Fig. 6A and B). Pw and OVA sensitized
(PwOVA) mice illustrated moderate mural and peri-airway
inflammation with accompanying mild mucous metaplasia
and moderate hyperplasia of the epithelium (Fig. 6C). The
combination of Pw immunization, B. pertussis infection and
OVA sensitization did not show enhanced pathology but only
moderate mucous metaplasia and moderate hyperplasia of the
epithelium (Fig. 6D). Given that previous work has shown
that B. pertussis infection in combination with OVA sensiti-
zation (BpOVA) displayed more severe airway inflammation
with a greater degree of both epithelial hyperplasia and mu-
cous metaplasia, it can be clearly seen here that Pw immu-
nization reduces the severity of airway pathology (Fig. 6D)
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Fig. 4. Pw immunization modulates the local cytokine response to B. pertussis infection and OVA sensitization. Diluted BALF (0.5 ml per mouse) was pooled
from five mice per group and concentrations of IL-5 (A), IFN- (B), IL-13 (C) and IL-10 (D) were determined by EIA. Results are representative of duplicate
experiments. Cytokine concentrations were assayed in triplicate with values expressed as mean cytokine concentration in diluted BALF (±S.E.M.). *P< 0.05
compared to the PwOVA treated group.
and reduces pulmonary resistance as indicated by plethys-
mography (Fig. 5D).
4. Discussion
The present study demonstrates that Pw immunization
protects against B. pertussis exacerbation of OVA-induced
airway hyperresponsiveness in a murine model. Pw immu-
nization suppresses antibody and cell mediated responses
against OVA sensitization in combination with B. pertussis
infection at both the local and systemic level, coupled with
a subsequent reduction in airway reactivity and pathology.
It has been previously shown that B. pertussis exacerbates
OVA-induced airway pathology leading to the development
of more pronounced allergen-induced airway inflammation
Table 2
Histological assessment of airway pathology
Treatment group Mucous metaplasia of
airway epithelium
Hyper plasia of airway
epithelium
Smooth muscle
hypertrophy of airway wall
Peri-airway/vascular
inflammationa
Overall degree E N L M F
Ctrl − − − − − − − − −
Bp − + + + − + ++ − −
Ova ++ ++ ++ ++b + ++ ++c − −
BpOVA +++ +++ ++ +++b ++ +++ +++c − −
Pw − − − − − − − − −
PwBp − + + − − − − − −
PwOVA + ++ + ++b ++ ++ ++c − −
PwBpOVA ++ ++ ++ ++b ++ ++ ++c − −
A semi-quantitative score (− absent, + mild, ++ moderate, +++ severe) was assigned to features of airway pathology observed according to previously described
criteria [17].
a Peri-airway/vascular inflammation was assessed in terms of overall degree and of numbers of infiltrating eosinophils (E), neutrophils (N), lymphocytes,
plasma cells and macrophages (L), mast cells (M) and in terms of circumscribing fibrosis (F).
b Inflammation extending into surrounding pulmonary interstitium and alveolar spaces.
c oundinMacrophage giant cells form part of inflammatory exudates within surr g alveolar spaces.
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Fig. 5. Pw immunization prior to B. pertussis infection decreases bronchial hyperresponsiveness to sensitizing antigen. Airway hyperreactivity in response
to increasing concentrations of inhaled methacholine (MCh) was measured by whole-body plethysmography. (A) Control and Bp infected mice (B), Pw and
PwBp (C), OVA and PwOVA (D), BpOVA and PwBpOVA groups, respectively. Results are representative of two experiments (n= 4) and values are expressed
as mean enhanced pause (PenH)±S.E.M., in groups where no errors are visible, error bars are shorter than the size of the data point symbol.
[17]. We demonstrate that Pw immunization protects against
this as well as reducing airway hyperresponsiveness.
The prevalence of asthma and allergic disease has in-
creased in many countries [39,40] and there has been spec-
ulation as to possible causes [41,42], including the possible
role of immunization in promoting allergic sensitization [43].
For example, pertussis vaccination acts as an adjuvant for
antigen-specific responses in laboratory animals [30,33]; a
specific IgE response to pertussis toxin itself has been iden-
tified in children receiving pertussis immunization [44]; and
vaccination with some other organisms such as Haemophilus
influenzae enhances histamine release in laboratory animals
[45]. Active pertussis toxin has a similar effect [46]. In ad-
dition, two studies have suggested that pertussis infection
increased the risk of atopy [47,48]. It is therefore theoreti-
cally possible that Pw immunization might contribute to the
development of allergic disease.
The goal of this study was to test whether immunization
with whole-cell pertussis (Pw) vaccine would protect against
B. pertussis exacerbation of allergic asthma. B. pertussis in-
fection modulates allergen priming and the severity of airway
pathology in a murine model[17]. It has been proposed that
IL-10 plays an essential role in modulating the immune re-
sponses by inducing towards regulatory T-cell responses[49]
however Lee et al have demonstrated that IL-10 induces IL-13
production in vivo and that this is responsible for the mucus,
but not the inflammatory/fibrotic effects of IL-10 [50]. In
the present study, we observe that Pw immunization prevents
induction of IL-10 and IL-13 and protects against airway hy-
perreactivity. Although IL-10 is known to act in an immune
regulatory manner, we and others have suggested that it has
broader functions that may not always protect against inflam-
matory disease [17,51]. For example, Grunstein et al. have
suggested that IL-10 may play an important role in allergic
asthma by acting directly on the airway smooth muscle it-
self [51]. Previous studies in humans have demonstrated that
IL-13 mRNA and protein levels are elevated in the lungs of
atopic and non-atopic asthmatics [52] suggesting that over
expression of IL-13 may predispose toward the development
of both types of asthma [53]. The reduction in both IL-10
and IL-13 at the systemic and local levels suggests that by
removing the damaging effects of pertussis infection and con-
sequently reducing IL-10 and IL-13, Pw exerts a protective
effect. Interestingly, very recent work by Kim et al has shown
that components of B. pertussis can inhibit airway hyperre-
sponsiveness [54]. That study demonstrated that unmethy-
lated CpG sequences from B. pertussis DNA inhibited Th2
cytokines in the airways via a TLR9 interaction [54]. Our
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Fig. 6. Whole-cell B. pertussis vaccine reduces the severity of airway pathology to sensitizing antigen both in the presence and absence of B. pertussis
infection. Representative morphological changes at 37 days in transverse sections of bronchioles from (A) Pw immunized mice showing no changes evident;
(B) Pw/Bp mice, minimal changes evident; (C) Pw/OVA treated mice, illustrating moderate mural and peri-airway inflammation with accompanying mild
mucous metaplasia (blue staining goblet cells) and moderate hyperplasia of epithelium; (D) Combined Pw/Bp/OVA treated group, illustrating a moderate
mural and peri-airway inflammation, moderate mucous metaplasia and moderate epithelial hyperplasia; (E) OVA sensitized group illustrating moderate mural
and peri-airway inflammation with accompanying moderate mucous metaplasia (blue staining goblet cells) and hyperplasia of epithelium; (F) combined
B. pertussis/OVA treated group illustrating severe mural and peri-airway inflammation, moderate epithelial hyperplasia and severe mucous metaplasia with
accompanying mucus plugging of the lumen. All sections are representative of groups of five mice per experiment, performed at least twice. Sections stained
with a combined Discombe’s/Alcian blue stain, original magnification 400×.
observation of reduced inflammation and OVA-specific IgE
(Figs. 2 and 6) in PwBpOVA mice is consistent with that
finding. TLR9 mediated reduction in Th2 cytokines can be
invoked in this situation, because these mice will be exposed
to bacterial DNA in a context where prior immunization will
limit tissue damage or the other immunomodulatory effects
of viable B. pertussis [17,54].
The most common formulation of the hygiene hypothesis
is based upon a lack of immunological stimuli in early in-
fancy that results in aberrant Th2 responses [10,12]. Clearly
infant pertussis immunization or infection could potentially
influence this process. Studies in neonatal mice support
our findings that Pw is a strong Th1 inducer, but it is less
effective in inducing antibody responses during this period
[28,55,56]. A study by Gruber et al. revealed no evidence for
an allergy promoting effect of common childhood vaccines
in a prospectively followed atopy risk-enhanced birth cohort
[26]. Moreover, they found that children with a better vac-
cination coverage seemed to be better protected against the
development of atopy in their second and third years of life. In
particular, measles/mumps, pertussis, and diphtheria/tetanus
immunization were associated with a transient reduction of
atopy, whereas immunization against polio and H. influenzae
had no effect. Furthermore, immunization of children with
Pw down regulated the IgE response to co-administered
diphtheria and tetanus toxoids [57]. In contrast, a study
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involving the effects of diphtheria–tetanus–pertussis (DTP)
or tetanus vaccination on allergies among children in the
U.S. reported that DTP or tetanus vaccination appeared to in-
crease the risk of allergies and related respiratory symptoms,
one contentious interpretation of this study is that vaccine
components may be responsible for a portion of the increased
prevalence of asthma and allergies in U.S. children [24].
We have established models that allow examination of the
mechanisms of interaction between protective immunization
and allergic sensitization. Pw immunization reduces IL-13
and IL-10 in BALF (Fig. 4C and D) and also protects against
airway hyperresponsiveness (Fig. 5D). These data indicate
that although Pw induces a similar immune response to B.
pertussis infection, these responses are not identical. Pw does
not enhance airway IL-13 and consequently does not enhance
but protects against the exacerbation of allergic responses. We
find no evidence of Pw contributing to allergic asthma, but
rather provide evidence of a mechanism whereby whole-cell
pertussis vaccination has a protective role.
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